– 100% of Patients Evaluable for Efficacy (N=9) Achieved Complete Response (CR) at the Initial 3-Month Timepoint –
– For Patients That Reached Additional Timepoints, 100% (N=6) Have Also Maintained a CR Through 6 Months and 100% (N=3) at the 9-Month Assessment –
– Treatment Related Adverse Events (AEs) Were Limited to Transient Grade 1-2 Local Genitourinary Symptoms and Immune-related AEs –
San Francisco, CA (UroToday.com) — CG Oncology, Inc., a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for patients with advanced cancer, announced preliminary Phase 2 study (CORE1) results for CG0070 in combination with KEYTRUDA® (pembrolizumab), for the treatment of patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).